The SEQUOIA arm D study demonstrates promising outcomes for treatment-naive patients with CLL, including high-risk patients.

It’s scary to think that we may have been using a surrogate — BMI — that may not have been all that accurate over the years," ...

In particular, they pointed to ivonescimab’s progression-free survival hazard ratio of 0.52 when paired with chemo. That ...

A common medication already used for autoimmune diseases such as rheumatoid arthritis is effective for patients with giant ...

Q. You’ve written about problems with low sodium levels due to blood pressure pills or even very low-sodium diets. Don’t ...

Puma Biotechnology remains undervalued despite steady neratinib sales and a promising, though early-stage, pipeline. Learn ...

The US Food and Drug Administration (FDA) has approved GSK's 200 mg/ml autoinjector of Benlysta for individuals aged five ...

Under the renewed deal, Bayer and Tsinghua University will work to enhance the drug discovery and development process across ...

Repare Therapeutics Inc. (NASDAQ: RPTX) is one of the best Canadian stocks with huge upside potential. As May began, Repare ...

While heart disease has been the leading cause of death in the U.S. for over a century, the past 50 years have seen a ...

Patients with both chronic kidney disease (CKD) and type 2 diabetes may benefit from therapy with finerenone and ...

Defect-free quadruple medication therapy significantly improved at discharge, 30 days in patients with heart failure with reduced ejection fraction.